I highly doubt that - any continued dosing from Phase IIb for participants post their trial if they decide to continue it in 18-24 months time would be separated the data wouldn't be released until after completion of the trial. It would just make the trial messy it would be under a separate protocol. I'd also assume it wont be a straight continuation as with the last trial the last time point measured is 4 & 8 week post treatment.
I highly doubt that - any continued dosing from Phase IIb for...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.004(6.25%) |
Mkt cap ! $61.30M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 7.1¢ | 6.5¢ | $198.2K | 2.885M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14845 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
0.004 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 7.1¢ | 6.6¢ | 295714 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PER (ASX) Chart |